drugset / Trial / NCT02216513

Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage

NCT02216513

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The investigators will test the central hypothesis that DFO treatment after SAH may improve cerebrovascular regulation, mitigate ischemic neural injury, and serve as an effective neuroprotectant against delayed ischemic injury after SAH.

Timeline

Start
2014-09
Primary completion
2015-06
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Deferoxamine Other / unclassified 20 mg/kg Intravenous